Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response

Open access
Golebski, Korneliusz, Layhadi, Janice A., Sahiner, Umit, Steveling-Klein, Esther H., Lenormand, Madison M., Li, Rachael C.Y., Bal, Suzanne M., Heesters, Balthasar A., Vilà-Nadal, Gemma, Hunewald, Oliver, Montamat, Guillem, HeFeng, Feng Q., Ollert, Markus, Fedina, Oleksandra, Lao-Araya, Mongkol, Vijverberg, Susanne J.H., Maitland-van der Zee, Anke-Hilse, van Drunen, Cornelis M., Fokkens, Wytske J., Durham, Stephen R., Spits, Hergen, Shamji, Mohamed H.·2021·Immunity

Abstract

The role of innate immune cells in allergen immunotherapy that confers immune tolerance to the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producing type 2 innate lymphoid cells (IL-10+ ILC2s) in modulating grass-pollen allergy. We demonstrate that KLRG1+ but not KLRG1- ILC2 produced IL-10 upon activation with IL-33 and retinoic acid. These cells attenuated Th responses and maintained epithelial cell integrity. IL-10+ KLRG1+ ILC2s were lower in patients with grass-pollen allergy when compared to healthy subjects. In a prospective, double-blind, placebo-controlled trial, we demonstrated that the competence of ILC2 to produce IL-10 was restored in patients who received grass-pollen sublingual immunotherapy. The underpinning mechanisms were associated with the modification of retinol metabolic pathway, cytokine-cytokine receptor interaction, and JAK-STAT signaling pathways in the ILCs. Altogether, our findings underscore the contribution of IL-10+ ILC2s in the disease-modifying effect by allergen immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.12.013

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 250

Metadata

Authors
Golebski, K., Layhadi, J. A., Sahiner, U., Steveling-Klein, E. H., Lenormand, M. M., Li, R. C. Y., Bal, S. M., Heesters, B. A., Vilà-Nadal, G., Hunewald, O., Montamat, G., HeFeng, F. Q., Ollert, M., Fedina, O., Lao-Araya, M., Vijverberg, S. J. H., Maitland-van der Zee, A.-H., van Drunen, C. M., Fokkens, W. J., Durham, S. R., Spits, H., & Shamji, M. H.
Venue
Immunity
Publisher
Elsevier BV
Published
2021-02
Volume
54
Issue
2
Pages
291-307.e7
ISSN
1074-7613 (ISSN-L)
OpenAlex
W3121106737
Cited by
250
References
6
FWCI
13.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. https://app.cochat.ai/papers/10.1016/j.immuni.2020.12.013
The paper
Golebski, K., Layhadi, J. A., Sahiner, U., Steveling-Klein, E. H., Lenormand, M. M., Li, R. C. Y., Bal, S. M., Heesters, B. A., Vilà-Nadal, G., Hunewald, O., Montamat, G., HeFeng, F. Q., Ollert, M., Fedina, O., Lao-Araya, M., Vijverberg, S. J. H., Maitland-van der Zee, A.-H., van Drunen, C. M., Fokkens, W. J., . . . Shamji, M. H. (2021). Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. https://doi.org/10.1016/j.immuni.2020.12.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.